

## Caribou Biosciences to Participate in Citi's 16th Annual BioPharma Virtual Conference

September 1, 2021

BERKELEY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a panel discussion entitled "Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy" on Thursday, September 9, 2021 at 10:40 am ET. The panel is being hosted at Citi's 16th Annual BioPharma Virtual Conference.

A live and archived webcast of the discussion will be accessible on the Events page of the Investors section on Caribou's website at <a href="https://www.cariboubio.com">www.cariboubio.com</a> for 30 days following the event.

## About Caribou Biosciences, Inc.

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences, Inc. Media Contact: Greg Kelley Ogilvy gregory.kelley@ogilvy.com 617-461-4023 Caribou Biosciences, Inc.
Investor Relations Contact:
Elizabeth Wolffe, Ph.D. and Sylvia Wheeler
Wheelhouse LSA
Iwolffe@wheelhouselsa.com
swheeler@wheelhouselsa.com